Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment#USA#Salt_Lake_City#Lipocine#LPCN_1154#PPD_Treatment
Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment
Lipocine Inc. has achieved 80% enrollment in its Phase 3 clinical trial for LPCN 1154, an innovative treatment for postpartum depression (PPD).
third-news.com
December 16, 2025 at 1:27 PM
Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment#USA#Salt_Lake_City#Lipocine#LPCN_1154#PPD_Treatment